Strausberg, May 26, 2025 – DERMAGO GmbH has successfully submitted the complete registration dossier for the dermatological generic Beloren in four countries. Beloren is based on the proven active ingredient azelaic acid and represents a high-quality alternative to the original product.
After more than 7 years of development, the final dossier comprises
300 individual documents with
over 4,500 pages
organized in 2,397 folders with
total of 5,639 files in the DMS system.
Beloren was first initiated as a project in 2017 – with a clear objective: dermatological quality “Made in Brandenburg”, combined with international standards and regulatory excellence.
“If you want to create real value in the pharmaceutical industry, you have to show staying power. Beloren shows that: We see things through to the end.”
– Sven Schimansky-Wabra, CEO DERMAGO GmbH
DERMAGO GmbH continues to position itself as a strong, independent drug developer with a clear focus on skin health. Investors, partners and distributors are invited to become part of the next phase of growth.
Translated with www.DeepL.com/Translator (free version)